Cluster of differentiation 244–Cluster of differentiation 48 interaction (CD244–CD48)

The CD244–CD48 interaction is a key regulatory pathway in the immune system, belonging to the Signaling Lymphocytic Activation Molecule (SLAM) family [UniProt, 2024]. CD244 (also known as 2B4) is a transmembrane receptor expressed on natural killer (NK) cells and cytotoxic T cells, while CD48 is its high-affinity ligand found on most hematopoietic cells [PubMed, 2021]. This interaction serves as a functional rheostat, where the signaling outcome—activating or inhibitory—is determined by the availability of intracellular adaptor proteins like SAP (SH2D1A) [Frontiers in Immunology, 2021]. In healthy states, it promotes cell adhesion and costimulation, but in chronic diseases such as cancer and viral infections, it often contributes to immune exhaustion by recruiting inhibitory phosphatases [NIH, 2025]. Therapeutic strategies targeting this axis include blocking antibodies to reverse T-cell and NK-cell dysfunction or using antibody-drug conjugates, such as SGN-CD48A, to eliminate CD48-positive malignant cells in multiple myeloma [NCI Drug Dictionary, 2024]. However, the dual nature of its signaling presents challenges, as disrupting the axis can potentially lead to autoimmunity or impaired self-tolerance [PubMed, 2021].

Other names

2B4–CD48 interactionSLAMF4–SLAMF2 interactionCD244–SLAMF2 interaction2B4–SLAMF2 interactionNatural killer cell receptor 2B4–CD48 interaction

The primary mechanisms of action include the blockade of the CD244–CD48 interaction to prevent inhibitory signaling and reverse immune exhaustion in T cells and NK cells [PubMed, 2021]. Additionally, antibody-drug conjugates (ADCs) such as SGN-CD48A target CD48-expressing malignant cells to deliver cytotoxic agents like monomethyl auristatin E (MMAE), inducing cell cycle arrest and apoptosis [NCI Drug Dictionary, 2024].